CYP1B1 Detox Gene and Toxin Clearance | Decoding Inflammation

By Alberto Rivera, MD · 2026-05-09 · 6 min read

A Phase I Enzyme With Dual Consequences

Cytochrome P450 1B1, encoded by CYP1B1, performs the body's first pass at metabolizing a broad class of substrates: exogenous polycyclic aromatic hydrocarbons from combustion, endogenous estrogens, and numerous pharmaceutical compounds. The enzyme's fundamental role is to add hydroxyl groups to these molecules, a process that can either facilitate their excretion or, in some cases, activate them into more reactive and potentially damaging intermediates.

This dual nature, detoxifier and bioactivator, makes CYP1B1 pharmacogenomics particularly consequential. The Leu432Val variant, rs1056836, shifts the enzyme's catalytic preference, producing a protein that more efficiently converts estradiol to 4-hydroxyestradiol, a genotoxic catechol estrogen, rather than the relatively benign 2-hydroxy pathway.

The Estrogen Metabolism Cascade

Estrogen metabolism is not a single reaction. It is a branched pathway in which CYP1B1, CYP1A1, and COMT compete for substrate. 4-Hydroxyestradiol, the product favored by the 432Val variant, can form DNA adducts if not efficiently methylated and cleared. COMT methylates catechol estrogens into inactive methoxyestrogens. When the Val/Val genotype is combined with low-activity COMT Met/Met, the result is both higher catechol estrogen production and slower clearance.

A 2025 case-control study in Cancer Epidemiology confirmed that the CYP1B1 Val/Val and COMT Met/Met compound genotype confers a substantially elevated risk of estrogen-sensitive malignancy in premenopausal women, independent of hormonal exposure. The genome, in this instance, assembles the risk from two individually moderate variants into a compounding vulnerability.

The Environmental Toxin Dimension

Beyond estrogen metabolism, CYP1B1 Val/Val carriers bioactivate polycyclic aromatic hydrocarbons, from tobacco smoke, grilled food, and air pollution, into reactive epoxides with greater efficiency than Leu/Leu carriers. These epoxides form DNA adducts, trigger oxidative stress, and activate NF-κB-mediated inflammatory signaling. The toxin load that a given environment imposes on the body is not fixed. It is filtered through the genome.

GENEFLAMMATION maps CYP1B1 alongside CYP1A1, COMT, GSTP1, and GSTM1 to construct a full phase I and phase II detoxification profile. The therapeutic output is a precise environmental modification and supplementation strategy that reduces both bioactivation burden and the inflammatory consequences of the toxin-genome interaction.